Home/Pipeline/DU385

DU385

Cancer

PreclinicalActive

Key Facts

Indication

Cancer

Phase

Preclinical

Status

Active

Company

Avidin

About Avidin

Avidin is a diversified biotech firm with a dual focus on therapeutic discovery and molecular diagnostics. Its most advanced program is Q134R, a clinical candidate for Alzheimer's disease developed in partnership with Aperus Pharma. The company also maintains active research in oncology and inflammation, and provides preclinical services and diagnostic products, supported by international scientific and industrial collaborations.

View full company profile

Therapeutic Areas

Oncology Neurodegenerative Diseases Infectious Diseases Inflammation

Other Cancer Drugs

Drug	Company	Phase	Status
Not Specified (Oncology Focus)	Narwhal Bio	Pre-clinical	Active
EDM Platform for Genetic Medicine	Coastar Therapeutics	Pre-clinical	Platform Development
CO-1	Caedo Oncology	Pre-clinical	Active R&D
Anti-CD99 monoclonal antibody	Caedo Oncology	Discovery/Pre-clinical	Proprietary antibody identified
Anti-HLA class I monoclonal antibody	Caedo Oncology	Discovery/Pre-clinical	Proprietary antibody identified
Triapine®	Nanopharmaceutics	Clinical	Active
Ammonium Tetrathiomolybdate	Nanopharmaceutics	Clinical	Active
Aza-TdC	Nanopharmaceutics	Clinical	Active
Undisclosed Oncology Program(s)	Cell BioEngines	Phase 1	Active
No-alpha IL-2 Mutein	SarcoMed USA	Pre-clinical	Active
PMIS Therapeutic	NaturemiRI	Preclinical/Clinical (unspecified)	Active
AUM302 (formerly IBL-302)	Inflection Biosciences	Pre-clinical (partnered)	Active